nach oben

Erschienen in:

01.12.2024 | Original Paper

Clinical features, management, and outcomes of patients with sterile endophthalmitis associated with intravitreal bevacizumab injection: retrospective case series

verfasst von: Ulviye Kivrak, Aysu Karatay Arsan, Güzide Akçay, Muhammed Nurullah Bulut, Hatice Selen Kanar, Aynur Oflaz Hacısalihoğlu, Şaban Şimşek

Erschienen in: International Ophthalmology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate clinical features, treatment protocol, outcomes, and complications that developed in this case series of 24 patients who had consecutive sterile endophthalmitis after intravitreal bevacizumab (IVB) injection.

Methods

In this retrospective case series, IVB was repackaged in individual aliquots from the three batches that were used on the same day. IVB was injected into 26 eyes of 26 patients due to diabetic macular edema, age-related macular degeneration, and branch retinal vein occlusion. All patients had intraocular inflammation. Patients were divided into two groups severe and moderate inflammation according to the intraocular inflammation. The medical records of all patients were reviewed. At each follow-up visit, the complete ophthalmologic examination was performed, including best corrected visual acuity (BCVA), intraocular pressure, biomicroscopy, and posterior fundus examination.

Results

Twenty-four of 26 patients were included in the study. Two patients were excluded from this study since they didn’t come to follow-up visits. The mean BCVA was 1.00 ± 0.52 Log MAR units before IVB. At the final visit, the BCVA was 1.04 ± 0.47 Log MAR units. These differences were not significant (p = 0.58). Of the 24 eyes, 16 eyes had severe, and 8 eyes had moderate intraocular inflammation. Eleven eyes in the severe inflammation group underwent pars plana vitrectomy due to intense vitreous opacity. Smear, culture results, and polymerase chain reaction results were negative.

Conclusion

Sterile endophthalmitis may occur after IVB injection. Differential diagnosis of sterile endophthalmitis from infective endophthalmitis is crucial to adjust the appropriate treatment and prevent long-term complications due to unnecessary treatment.

Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434. https://doi.org/10.1056/NEJMoa021491CrossRefPubMedPubMedCentral

Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–1047. https://doi.org/10.1016/j.ophtha.2005.02.007CrossRefPubMed

Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ et al (2008) Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American collaborative retina study group at 6 months of follow-up. Retina 28:212–219. https://doi.org/10.1097/IAE.0b013e3181619beeCrossRefPubMed

Song JH, Byeon SH, Lee SC, Koh HJ, Kwon OW (2008) Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica 223:85–92. https://doi.org/10.1159/000175312CrossRefPubMed

Glassman AR, Wells JA 3rd, Josic K, Maguire MG, Antoszyk AN, Baker C et al (2020) Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T extension study). Ophthalmology 127(9):1201–1210. https://doi.org/10.1016/j.ophtha.2020.03.021CrossRefPubMed

Hartnett ME (2020) Retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor. AmJ Ophthalmol 218:208–213. https://doi.org/10.1016/j.ajo.2020.05.025CrossRef

Storey PP, Ho V, Yeh S, Reddy S, Fang-Yen NH, Pequignot E et al (2015) Incidence of sustained ocular hypertension using prepackaged versus freshly prepared intravitreal bevacizumab for neovascular age-related macular degeneration. Retina 35(10):1992–2000. https://doi.org/10.1097/IAE.0000000000000620CrossRefPubMed

Jeong S, Sagong M, Chang W (2017) Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. BMC Ophthalmol 17(1):25. https://doi.org/10.1186/s12886-017-0417-3CrossRefPubMedPubMedCentral

Karabag RY, Parlak M, Cetin G, Yaman A, Osman SA (2015) Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports. Digit J Ophthalmol 21(1):8–10. https://doi.org/10.5693/djo.01.2014.07.001CrossRefPubMedPubMedCentral

10.

Marticorena J, Romano V, Gómez-Ulla F (2012) Sterilized endophthalmitis after intravitreal injections. Mediat Inflamm 2012:928123. https://doi.org/10.1155/2012/928123CrossRef

11.

Sen S, Mishra C, Kannan NB, Ramasamy K, Rameshkumar G, Lalitha P (2021) Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections: a multicentric study. Semin Ophthalmol 36(5 6):413–422. https://doi.org/10.1080/08820538.2021CrossRefPubMed

12.

Mason JO III, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO et al (2008) Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 28(4):564–567. https://doi.org/10.1097/IAE.0b013e3181633feeCrossRefPubMed

13.

Williams PD, Chong D, Fuller T, Callanan D (2016) Noninfectious vitritis after intravitreal injection of anti-VEGF agents: variations in rates and presentation by medication. Retina 36(5):909–913. https://doi.org/10.1097/IAE.0000000000000801CrossRefPubMed

14.

Anderson WJ, da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB (2021) Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous 7(1):37. https://doi.org/10.1186/s40942-021-00307-7CrossRefPubMedPubMedCentral

15.

Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516. https://doi.org/10.1016/j.ajo.2005.03.057CrossRefPubMed

16.

Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A et al (2018) 2018 Update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica 239(4):181–193. https://doi.org/10.1159/000486145CrossRefPubMed

17.

Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36(4):336–339CrossRefPubMed

18.

Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36(4):331–335CrossRefPubMed

19.

Schwartz SG, Flynn HW Jr, Emerson GG, Choudhry N, Ferrone PJ, Goldberg RA et al (2019) Distinguishing between infectious endophthalmitis and noninfectious inflammation following intravitreal anti-VEGF Injection. J Vitreoretin Dis 3(1):42–44CrossRef

20.

Fine HF, Despotidis GD, Prenner JL (2015) Ocular inflammation associated with antivascular endothelial growth factor treatment. Curr Opin Ophthalmol 26(3):184–187. https://doi.org/10.1097/ICU.0000000000000154CrossRefPubMed

21.

Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otani A, Tamuara H et al (2010) Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina 30(3):485–490. https://doi.org/10.1097/IAE.0b013e3181bd2d51CrossRefPubMed

22.

Entezari M, Ramezani A, Ahmadieh H, Ghasemi H (2014) Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab. Indian J Ophthalmol 62(4):468–471. https://doi.org/10.4103/0301-4738.111192CrossRefPubMedPubMedCentral

23.

Bakri SJ, Larson TA, Edwards AO (2008) Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 246(5):779–781. https://doi.org/10.1007/s00417-007-0754-7CrossRefPubMed

24.

Base M, Singh RP, Chung JY, Lowder CY, Perez VL, Kaiser PK (2007) Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. AmJ Ophthalmol 144(1):50–54. https://doi.org/10.1016/j.ajo.2007.03.051CrossRef

25.

Casparis H, Wolfensberger TJ, Becker M, Eich G, Graf N, Ambresin A et al (2014) Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina 34(1):12–17. https://doi.org/10.1097/IAE.0b013e31829f74b0CrossRefPubMed

26.

Chong DY, Anand R, Williams PD, Qureshi JA, Callayan DG (2010) Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina 30(9):1432–1440. https://doi.org/10.1097/IAE.0b013e3181dc04CrossRefPubMed

27.

Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA (2003) Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121(9):1279–1282. https://doi.org/10.1001/archopht.121.9.1279CrossRefPubMed

28.

Wickremasinghe SS, Michalova K, Gilhotra J, Guymer RH, Harper CA, Wong TY et al (2008) Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 115(11):1911–1915. https://doi.org/10.1016/j.ophtha.2008.05.007CrossRefPubMed

29.

Wang F, Yu S, Liu K, Chen FE, Song Z, Zhang X et al (2013) Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology 120(2):355–361. https://doi.org/10.1016/j.ophtha.2012.07.083CrossRefPubMed

30.

Melo GB, Cruz N, Emerson GG, Rezende FA, Meyer CH, Uchiyama S et al (2021) Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections. Prog Retin Eye Res 80:100862. https://doi.org/10.1016/j.preteyeres.2020.100862CrossRefPubMed

31.

Uchino T, Miyazaki Y, Yamazaki T, Kagawa Y (2017) Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice. J Pharm Pharmacol 69(10):1341–1351. https://doi.org/10.1111/jphp.12765CrossRefPubMed

32.

Ahrer K, Buchacher A, Iberer G, Jungbauer A (2006) Thermodynamic stability and formation of aggregates of human immunoglobulin G characterized by differential scanning calorimetry and dynamic light scattering. J Biochem Biophys Methods 66(1 3):73–86. https://doi.org/10.1016/j.jbbm.2005.12.003CrossRefPubMed

33.

Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF (2011) Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 52(2):1023–1034. https://doi.org/10.1167/iovs.10-6431CrossRefPubMedPubMedCentral

34.

Freire E, Schon A, Hutchins BM, Brown RK (2013) Chemical denaturation as a tool in the formulation optimization of biologics. Drug Disco Today 18(19 20):1007–1013. https://doi.org/10.1016/j.drudis.2013.06.005CrossRef

35.

Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA (2011) Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 118(10):2028–2034. https://doi.org/10.1016/j.ophtha.2011.02.034CrossRefPubMed

36.

Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American collaborative retina study group (PACORES). Graefes Arch Clin Exp Ophthalmol 246(1):81–87. https://doi.org/10.1007/s00417-007-0660-zCrossRefPubMed

37.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431. https://doi.org/10.1056/NEJMoa054481CrossRefPubMed

38.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432–1444. https://doi.org/10.1056/NEJMoa062655CrossRefPubMed

39.

Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908. https://doi.org/10.1056/NEJMoa1102673CrossRefPubMed

40.

Heier Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548. https://doi.org/10.1016/j.ophtha.2012.09.06CrossRefPubMed

41.

Peyman GA, Lad EM, Moshfeghi DM (2009) Intravitreal injection of therapeutic agents. Retina 29(7):875–912. https://doi.org/10.1097/IAE.0b013e3181a94f01CrossRefPubMed

Titel: Clinical features, management, and outcomes of patients with sterile endophthalmitis associated with intravitreal bevacizumab injection: retrospective case series
verfasst von: Ulviye Kivrak
Aysu Karatay Arsan
Güzide Akçay
Muhammed Nurullah Bulut
Hatice Selen Kanar
Aynur Oflaz Hacısalihoğlu
Şaban Şimşek
Publikationsdatum: 01.12.2024
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 1/2024
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-024-03134-5

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Clinical features, management, and outcomes of patients with sterile endophthalmitis associated with intravitreal bevacizumab injection: retrospective case series

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

A new computer-aided diagnosis tool based on deep learning methods for automatic detection of retinal disorders from OCT images

Long-term ocular surface stability in conjunctivolimbal autograft and ocular surface safety in the donor eyes

New advances in medical management of dry eye: optimizing treatment strategies for enhanced relief

Actinic conjunctivitis and its relationship with prurigo in an indigenous population from the Highlands of Chiapas, Mexico

A meta-analysis of the efficacy of two-wall orbital decompression operations for thyroid-associated ophthalmopathy

Ocular complications in adults with psoriasis: a cross-sectional study in a referral center in Brazil

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde